Abstract
Background: Patients with recurrent or advanced endometrial cancer (EC) who progress after platinum-based chemotherapy have limited treatment options and poor prognosis. This Phase II trial (NCT04157491) investigated the efficacy, safety, and potential biomarkers of the combination of sintilimab (anti-PD-1) and anlotinib (multi-targeted TKI). Methods: 23 patients were enrolled and treated with sintilimab and anlotinib. The primary endpoint was objective response rate (ORR). Genomic analysis was performed to identify biomarkers. Results: The ORR was 73.9%, with a disease control rate of 91.3%. Efficacy was observed in both MSI-H/dMMR (100% ORR) and MSS/pMMR (57.1% ORR) subgroups. Mutations in the Homologous Repair (HR) pathway and LYN gene were identified as potential biomarkers for response and resistance, respectively. Conclusion: Sintilimab plus anlotinib demonstrates robust antitumor activity and manageable toxicity in advanced EC, representing a promising "chemo-free" second-line strategy.
Introduction
Endometrial cancer (EC) is a significant health burden with rising incidence and mortality. For patients failing first-line platinum-based therapy, second-line options are limited. Immunotherapy has shown efficacy primarily in the ~30% of patients with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) status. The majority of patients have microsatellite stable (MSS) or proficient mismatch repair (pMMR) tumors, which are often resistant to PD-1/PD-L1 inhibitors. Combining immunotherapy with anti-angiogenic agents like anlotinib may overcome this resistance by modulating the tumor microenvironment. This study evaluates the sintilimab plus anlotinib combination in a Chinese patient population.
Methods
This was a single-arm, open-label Phase II trial. Eligible patients had recurrent or advanced EC and had progressed after at least one line of platinum-based chemotherapy. Patients received sintilimab (200 mg IV every 3 weeks) and anlotinib (12 mg orally, 2 weeks on/1 week off). Response was assessed using irRECIST criteria. Exploratory biomarker analyses included Whole Exome Sequencing (WES) and a 425-gene targeted panel on tumor tissue and blood.
Results
A total of 23 patients were evaluable for efficacy. The objective response rate (ORR) was 73.9% (17/23), including 4 complete responses (CR) and 13 partial responses (PR). The disease control rate (DCR) reached 91.3%.
The median time to response was 2.8 months. At a median follow-up of 15.4 months, the median progression-free survival (PFS) had not been reached. Subgroup analysis showed a 100% ORR in MSI-H/dMMR patients and a 57.1% ORR in MSS/pMMR patients, highlighting the regimen's efficacy in typically immunotherapy-resistant tumors.
Biomarker analysis identified mutations in the Homologous Repair (HR) pathway (e.g., BRCA2, ATM) as a potential positive predictor, with a 100% response rate in mutated patients. Conversely, LYN mutations were associated with significantly shorter PFS, indicating a potential mechanism for treatment resistance.
Safety
The safety profile was manageable. Grade 3/4 adverse events occurred in 50% of patients. Notably, Grade 3 hypertension occurred in only 4.3% of patients, suggesting better tolerability compared to other anti-angiogenic combinations used in this setting.
Discussion
The combination of sintilimab and anlotinib provides a highly effective and durable treatment option for patients with advanced EC, regardless of microsatellite status. The high ORR in the MSS/pMMR subgroup is particularly encouraging. The identification of HR pathway and LYN mutations as biomarkers offers a path toward personalized treatment strategies. While limited by a small sample size, these results support further investigation in larger, randomized trials.
Summary updated